Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Guidance On Desired Data Might Meet The Goals Of Parallel Review More Reasonably, Former Official Gottlieb Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

AEI's Scott Gottlieb, a former official at FDA and CMS, offers his insights into the proposed parallel review program during Avalere conference.
Advertisement

Related Content

IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions

Topics

Advertisement
UsernamePublicRestriction

Register

PS071688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel